Business Description
Chengda Pharmaceuticals Co Ltd
ISIN : CNE100005766
Share Class Description:
SZSE:301201: Class ACompare
Compare
Traded in other countries / regions
301201.China IPO Date
2022-01-20Description
Chengda Pharmaceuticals Co Ltd is engaged in the research and development, production and sales of L-carnitine series products. The company mainly produces raw materials, food additives, feed additives, antibiotics, anti-cancer, anti-virus and other series of pharmaceutical intermediates. The products are sold to more than 30 countries and regions.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1973.5 | |||||
| Equity-to-Asset | 0.93 | |||||
| Debt-to-EBITDA | 0.01 | |||||
| Interest Coverage | 22.07 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 14.58 | |||||
| Beneish M-Score | -2.39 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -5.9 | |||||
| 3-Year EBITDA Growth Rate | -13.6 | |||||
| 3-Year EPS without NRI Growth Rate | -21.9 | |||||
| 3-Year Book Growth Rate | 55.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 68.64 | |||||
| 9-Day RSI | 61.11 | |||||
| 14-Day RSI | 58 | |||||
| 3-1 Month Momentum % | 22.74 | |||||
| 6-1 Month Momentum % | 20.02 | |||||
| 12-1 Month Momentum % | -16.4 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.28 | |||||
| Quick Ratio | 8.46 | |||||
| Cash Ratio | 7.51 | |||||
| Days Inventory | 216.4 | |||||
| Days Sales Outstanding | 85.79 | |||||
| Days Payable | 215.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.86 | |||||
| Dividend Payout Ratio | 0.44 | |||||
| Forward Dividend Yield % | 0.86 | |||||
| 5-Year Yield-on-Cost % | 0.86 | |||||
| 3-Year Average Share Buyback Ratio | -10.1 | |||||
| Shareholder Yield % | 0.86 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 44.31 | |||||
| Operating Margin % | 9.5 | |||||
| Net Margin % | 17.64 | |||||
| FCF Margin % | -47.48 | |||||
| ROE % | 3.12 | |||||
| ROA % | 2.91 | |||||
| ROIC % | 3.56 | |||||
| 3-Year ROIIC % | -7.17 | |||||
| ROC (Joel Greenblatt) % | 10.8 | |||||
| ROCE % | 3.61 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 50.33 | |||||
| PE Ratio without NRI | 50.66 | |||||
| Shiller PE Ratio | 14.71 | |||||
| PEG Ratio | 3.54 | |||||
| PS Ratio | 9 | |||||
| PB Ratio | 1.6 | |||||
| Price-to-Tangible-Book | 1.63 | |||||
| Price-to-Operating-Cash-Flow | 34.68 | |||||
| EV-to-EBIT | 28.74 | |||||
| EV-to-EBITDA | 28.74 | |||||
| EV-to-Revenue | 5.88 | |||||
| EV-to-FCF | -11.47 | |||||
| Price-to-GF-Value | 0.87 | |||||
| Price-to-Peter-Lynch-Fair-Value | 4.64 | |||||
| Price-to-Graham-Number | 1.91 | |||||
| Price-to-Net-Current-Asset-Value | 2.75 | |||||
| Price-to-Net-Cash | 3.51 | |||||
| Earnings Yield (Greenblatt) % | 3.48 | |||||
| FCF Yield % | -5.28 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Chengda Pharmaceuticals Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 397.812 | ||
| EPS (TTM) (Â¥) | 0.459 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 36.97 | ||
| 14-Day RSI | 58 | ||
| 14-Day ATR (Â¥) | 1.078819 | ||
| 20-Day SMA (Â¥) | 22.4635 | ||
| 12-1 Month Momentum % | -16.4 | ||
| 52-Week Range (Â¥) | 14.6 - 27.17 | ||
| Shares Outstanding (Mil) | 154.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Chengda Pharmaceuticals Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Chengda Pharmaceuticals Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Chengda Pharmaceuticals Co Ltd Frequently Asked Questions
What is Chengda Pharmaceuticals Co Ltd(SZSE:301201)'s stock price today?
The current price of SZSE:301201 is ¥23.10. The 52 week high of SZSE:301201 is ¥27.17 and 52 week low is ¥14.60.
When is next earnings date of Chengda Pharmaceuticals Co Ltd(SZSE:301201)?
The next earnings date of Chengda Pharmaceuticals Co Ltd(SZSE:301201) is .
Does Chengda Pharmaceuticals Co Ltd(SZSE:301201) pay dividends? If so, how much?
The Dividend Yield %  of Chengda Pharmaceuticals Co Ltd(SZSE:301201) is 0.86% (As of Today), Highest Dividend Payout Ratio of Chengda Pharmaceuticals Co Ltd(SZSE:301201) was 0.86. The lowest was 0.44. And the median was 0.74. The  Forward Dividend Yield % of Chengda Pharmaceuticals Co Ltd(SZSE:301201) is 0.86%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers